CSBR Stock Overview
A technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Champions Oncology, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.71 |
52 Week High | US$7.13 |
52 Week Low | US$3.60 |
Beta | 0.45 |
11 Month Change | 1.62% |
3 Month Change | -5.04% |
1 Year Change | -16.64% |
33 Year Change | -54.18% |
5 Year Change | -14.98% |
Change since IPO | -60.75% |
Recent News & Updates
Recent updates
It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)
Jun 14Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Jul 21We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16Champions Oncology beats on revenue
Dec 14Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04Shareholder Returns
CSBR | US Life Sciences | US Market | |
---|---|---|---|
7D | 2.4% | 0.8% | 1.9% |
1Y | -16.6% | 13.1% | 32.8% |
Return vs Industry: CSBR underperformed the US Life Sciences industry which returned 11.9% over the past year.
Return vs Market: CSBR underperformed the US Market which returned 30.2% over the past year.
Price Volatility
CSBR volatility | |
---|---|
CSBR Average Weekly Movement | 9.4% |
Life Sciences Industry Average Movement | 8.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CSBR has not had significant price volatility in the past 3 months.
Volatility Over Time: CSBR's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1985 | 210 | Ronnie Morris | www.championsoncology.com |
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.
Champions Oncology, Inc. Fundamentals Summary
CSBR fundamental statistics | |
---|---|
Market cap | US$62.26m |
Earnings (TTM) | -US$3.40m |
Revenue (TTM) | US$51.66m |
1.2x
P/S Ratio-18.8x
P/E RatioIs CSBR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CSBR income statement (TTM) | |
---|---|
Revenue | US$51.66m |
Cost of Revenue | US$28.79m |
Gross Profit | US$22.87m |
Other Expenses | US$26.26m |
Earnings | -US$3.40m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.25 |
Gross Margin | 44.27% |
Net Profit Margin | -6.58% |
Debt/Equity Ratio | 0% |
How did CSBR perform over the long term?
See historical performance and comparison